研究人员开发靶向 EpCAM 和 CLDN3 的双特异性抗体偶联药物（BsADC），有效抑制肿瘤生长且毒性低，为实体瘤治疗带来新选择。 在癌症治疗的战场上，抗体偶联药物（ADCs）就像是精准制导的导弹，它将抗体的特异性与细胞毒性药物的强大杀伤力相结合，能够精准地 ...

Epithelial cell adhesion molecule (EpCAM) is a biomarker for epithelial cell-derived tumors. However, the specific role of EpCAM itself in early-stage hepatocellular carcinoma progression remains ...

Evaluating disparities in prostate cancer-related mortality among diabetic adults in the United States and Texas: A 21-year observational study (1999-2020). This is an ASCO Meeting Abstract from the ...

Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase ...